AbbVie’s HCV regimen receives FDA breakthrough designation
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation (BTD) forAbbVie‘s investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P) for the treatment of patients with chronic hepatitis C virus (HCV) who failed previous therapy with direct-acting antivirals (DAAs) in genotype 1 (GT1), including therapy with an NS5A inhibitor and/or protease inhibitor.
Click on this link for more information.
